Kerecis is developing the MariGen™ Omega3 Extra Cellular Matrix technology for use in products to treat chronic wounds and for abdominal wall reconstruction. Our patent pending fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.

Company History

Kerecis was established in late 2007 in Reykjavik, Iceland. The company gradually increased its operations focusing on building the basic MariGen™ platform during 2008 and 2009. The company completed its seed round late 2009 and is currently raising a "A" round targeting a close in 2011.

The new round will finance the completion of clinical studies, FDA 5.10k registrations and CE marking. The company is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical tests. Ideal potential technology licensees will have the ability to accelerate regulatory approvals and the market launch of these proprietary devices or provide access to key markets outside of the US.